Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
Pacific Biosciences (PACB) and Invitae Corporation announced an expansion of their collaboration to develop a high-throughput HiFi sequencing platform, integrating technology from Omniome, Inc. This partnership aims to enhance sequencing accuracy and sensitivity, particularly for cancer diagnostics and pathogen detection. The integration of short read sequencing technology is expected to lower analysis costs and improve clinical insights. The collaboration will commence in the second half of 2021, contingent on the completion of PACB’s acquisition of Omniome.
Pacific Biosciences (PACB) has announced a definitive agreement to acquire Omniome for approximately $800 million. The merger aims to combine Omniome's short-read sequencing technology with PacBio's long-read solutions, enhancing their market offering in genomics. The transaction includes $300 million in cash and stock, with additional milestone payments of $200 million. A concurrent $300 million PIPE financing will support the acquisition. PacBio reports preliminary revenue of $30.5 million for Q2 2021, marking a 78% growth year-over-year.
Pacific Biosciences of California (NASDAQ: PACB) announced its quarterly conference call to discuss the second quarter 2021 financial results scheduled for August 3, 2021, at 4:30 pm ET. The call will be accessible via webcast on the company's investor relations website. Pacific Biosciences focuses on providing scientists with long-read sequencing technology through its innovative instruments, enhancing research in genomics and epigenomics across various fields.
Pacific Biosciences (Nasdaq: PACB) is partnering with Rady Children’s Institute for Genomic Medicine to utilize HiFi Sequencing for rare disease studies. This collaboration aims to enhance the identification of genetic variants that standard short-read sequencing methods often miss. Preliminary results revealed an average of 37 missense mutations in known disease genes, showcasing the efficacy of long-read sequencing in diagnosing rare diseases affecting approximately 25 million Americans. The study is currently underway, seeking to improve diagnoses for critically ill pediatric patients.
Pacific Biosciences (NASDAQ: PACB) announced the grant of stock options and restricted stock units (RSUs) to a new employee on June 7, 2021. The compensation includes 80,000 stock options and 40,000 RSUs, in accordance with the 2020 Inducement Equity Incentive Plan. The options have an exercise price of $27.94 per share, aligned with the closing stock price on the grant date. The vesting schedule includes a one-year cliff for options, with monthly vesting thereafter, while RSUs vest over four years.
PacBio Appoints Neil Ward as VP and GM for EMEA
Pacific Biosciences (NASDAQ: PACB) has appointed Neil Ward as Vice President and General Manager for its EMEA region, aiming to enhance its commercial strategy. Ward brings over 20 years of experience in genomics and has previously held a senior role at Illumina, contributing to major genomics projects. The company is expanding its sales team and commercial infrastructure to capitalize on the growing demand for long-read sequencing technology, positioning itself for future growth in the genomics market.
Pacific Biosciences (PACB) announces three key appointments to enhance its leadership team. Dr. Catherine Ball becomes Senior Vice President of Research, focusing on expanding research and technology development. Kathleen Lynch joins as Head of Global Government Affairs and Communications, bringing extensive experience from Illumina and other firms. Michele Farmer is appointed Chief Accounting Officer, also from Illumina, with over 16 years in finance. These strategic hires aim to drive growth and innovation within the company.
Pacific Biosciences (NASDAQ: PACB) has announced its executives will participate in two upcoming investor conferences. The first is the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:00 p.m. EDT. The second is the UBS Global Healthcare Virtual Conference on May 25, 2021, at 11:00 a.m. EDT. Live webcasts will be available on the company's investors page, and replays will be accessible for at least 30 days post-presentation. This engagement underscores PACB's commitment to transparency and investor relations.
Pacific Biosciences reported an impressive first quarter for 2021, achieving $29.0 million in revenue, an 86% increase from $15.6 million in Q1 2020. The company placed 41 Sequel II/IIe systems, boosting the total installed base to 244 systems compared to 125 a year prior. Instrument revenue surged to $14.9 million, while consumables revenue grew to $10.4 million. Despite increasing operating expenses of $46.7 million, the company faced a net loss of $87.4 million, primarily due to a $52 million repayment to Illumina. Cash reserves stood at $1,160.3 million.
Pacific Biosciences (NASDAQ: PACB) announced the nomination of Dr. Hannah Valantine for election to its Board of Directors as a Class II director during the 2021 Annual Meeting. Dr. Valantine, a prominent figure in cardiovascular medicine and workforce diversity, holds a professorship at Stanford University and has previously been the Chief Officer for Scientific Workforce Diversity at the NIH. Her expertise aligns with PacBio's strategic goals. Dr. Michael Hunkapiller will not seek re-election but will remain on the Board until the Annual Meeting.